WALTHAM, Mass. — Thermo Fisher Scientific has announced a strategic collaboration with HealthVerity to strengthen data-driven clinical development and real-world evidence generation for biopharma companies.
Under the agreement, Thermo Fisher’s PPD clinical research business will gain enterprise-level access to HealthVerity’s TaXOnomy claims dataset, which includes information from more than 270 million de-identified patient records across the U.S. healthcare system.
The expanded access is expected to provide deeper insights into disease prevalence, treatment patterns, and provider activity. Company officials said the data will support improvements in trial feasibility, site selection, patient recruitment, and real-world evidence generation.
“This collaboration advances our ability to integrate high-quality, linked healthcare data into clinical development,” said Krishna Cheriath, vice president, head of clinical research digital and AI, biopharma services, Thermo Fisher Scientific. “By utilizing one of the largest integrated healthcare data ecosystems with our AI-enabled analytics, we can generate robust real-world evidence to support our customers across the clinical and post-approval continuum.”
The agreement also gives Thermo Fisher access to more than 70 curated data sources, including electronic medical records, laboratory data, and other specialty datasets. The company said the combination of longitudinal claims data and linked datasets will enable more precise site selection and faster study startup timelines.
In addition, the collaboration is expected to enhance real-world evidence and health economics and outcomes research capabilities across PPD CorEvitas Clinical Registries and PPD Evidera solutions, allowing for faster analytics and expanded registry-linked claims analysis.
“We’re proud to support Thermo Fisher’s PPD clinical research business in advancing data-driven clinical development,” said Joseph Satili, chief commercial officer, HealthVerity. “With enterprise access to robust real-world insights, teams can move faster and with greater confidence—from feasibility through evidence generation—improving how studies are designed and executed.”
Thermo Fisher said the collaboration will provide greater flexibility in delivering data-driven services while maintaining privacy protections and data governance standards. The move also reflects the company’s continued investment in digital tools aimed at improving clinical development efficiency and patient outcomes.
